Want to see SMMT full AI Analyst Report?

Summit Therapeutics (SMMT) Stock Forecast & Price Target

1,951 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SMMT Analyst Ratings

Moderate Buy

7 Buy

4 Hold

1 Sell

Based on 12 analysts giving stock ratings to

Summit

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SMMT Stock 12 Month Forecast

Average Price Target

$27.68

▲(102.64% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is $27.68 with a high forecast of $41.00 and a low forecast of $9.80. The average price target represents a 102.64% change from the last price of $13.66.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","42":"$42","16.5":"$16.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16.5,25,33.5,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.38,16.427692307692308,18.475384615384616,20.523076923076925,22.57076923076923,24.61846153846154,26.666153846153847,28.713846153846156,30.761538461538464,32.80923076923077,34.85692307692308,36.90461538461538,38.95230769230769,{"y":41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.38,15.403076923076924,16.426153846153845,17.44923076923077,18.472307692307695,19.495384615384616,20.518461538461537,21.54153846153846,22.564615384615387,23.587692307692308,24.61076923076923,25.633846153846154,26.65692307692308,{"y":27.68,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.38,14.027692307692309,13.675384615384615,13.323076923076924,12.970769230769232,12.618461538461538,12.266153846153847,11.913846153846155,11.561538461538461,11.20923076923077,10.856923076923078,10.504615384615384,10.152307692307692,{"y":9.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.49,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.49,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.19,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.92,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.115,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$41.00

Average Price Target$27.68

Lowest Price Target$9.80

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Salveen Richter

Goldman Sachs

$41

Buy

200.15%

Upside

Reiterated

07/28/26

Summit Therapeutics: KOL Backing for Ivonescimab in NSCLC Reinforces Buy Rating and Unchanged $41 Price Target

Dara Azar

Stifel Nicolaus

$38

Buy

178.18%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Argenx Se (NASDAQ: ARGX)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

07/27/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Gossamer Bio (NASDAQ: GOSS)

Unknown Analyst

Clear Street

Not Ranked

Clear Street

$31

Buy

126.94%

Upside

Reiterated

07/27/26

Clear Street Sticks to Its Buy Rating for Summit Therapeutics (SMMT)

Mohit Bansal

Wells Fargo

$30

Buy

119.62%

Upside

Reiterated

07/27/26

Analysts Conflicted on These Healthcare Names: HCA Healthcare (NYSE: HCA), Summit Therapeutics (NASDAQ: SMMT) and Neuphoria Therapeutics (NASDAQ: NEUP)

Faisal Khurshid

Jefferies

$17→$15

Hold

9.81%

Upside

Reiterated

07/24/26

Summit Therapeutics price target lowered to $15 from $17 at JefferiesSummit Therapeutics price target lowered to $15 from $17 at Jefferies

Etzer Darout

Barclays

$18

Hold

31.77%

Upside

Reiterated

07/24/26

Summit Therapeutics (SMMT) Gets a Hold from Barclays

Kelsey Goodwin

Piper Sandler

$16

Hold

17.13%

Upside

Reiterated

07/24/26

Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT)

Yigal Nochomovitz

Citi

$40

Buy

192.83%

Upside

Reiterated

07/24/26

Buy Rating Reaffirmed on Robust HARMONi Data and BLA Progress; $40 Price Target Maintained

Mitchell Kapoor

H.C. Wainwright

―

Hold

―

Reiterated

07/24/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Molina Healthcare (NYSE: MOH) and Johnson & Johnson (NYSE: JNJ)

Bradley Canino

Guggenheim

$40→$38

Buy

178.18%

Upside

Assigned

07/23/26

Summit Therapeutics price target lowered to $38 from $40 at GuggenheimSummit Therapeutics price target lowered to $38 from $40 at Guggenheim

Jeffrey Walch

Bernstein

$7.7→$9.8

Sell

-28.26%

Downside

Reiterated

06/21/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (NASDAQ: DMRA), Summit Therapeutics (NASDAQ: SMMT) and Elicio Therapeutics (NASDAQ: ELTX)

Cory Kasimov

Evercore ISI

$34

Buy

148.90%

Upside

Reiterated

05/01/26

Evercore ISI Sticks to Their Buy Rating for Summit Therapeutics (SMMT)

Asthika Goonewardene

Truist Financial

$35

Buy

156.22%

Upside

Reiterated

02/24/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (NYSE: HUM), Summit Therapeutics (NASDAQ: SMMT) and Intuitive Surgical (NASDAQ: ISRG)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Summit Therapeutics initiated with a Peer Perform at Wolfe ResearchSummit Therapeutics initiated with a Peer Perform at Wolfe Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Salveen Richter

Goldman Sachs

$41

Buy

200.15%

Upside

Reiterated

07/28/26

Summit Therapeutics: KOL Backing for Ivonescimab in NSCLC Reinforces Buy Rating and Unchanged $41 Price Target

Dara Azar

Stifel Nicolaus

$38

Buy

178.18%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Argenx Se (NASDAQ: ARGX)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

07/27/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Gossamer Bio (NASDAQ: GOSS)

Unknown Analyst

Clear Street

Not Ranked

Clear Street

$31

Buy

126.94%

Upside

Reiterated

07/27/26

Clear Street Sticks to Its Buy Rating for Summit Therapeutics (SMMT)

Mohit Bansal

Wells Fargo

$30

Buy

119.62%

Upside

Reiterated

07/27/26

Analysts Conflicted on These Healthcare Names: HCA Healthcare (NYSE: HCA), Summit Therapeutics (NASDAQ: SMMT) and Neuphoria Therapeutics (NASDAQ: NEUP)

Faisal Khurshid

Jefferies

$17→$15

Hold

9.81%

Upside

Reiterated

07/24/26

Summit Therapeutics price target lowered to $15 from $17 at JefferiesSummit Therapeutics price target lowered to $15 from $17 at Jefferies

Etzer Darout

Barclays

$18

Hold

31.77%

Upside

Reiterated

07/24/26

Summit Therapeutics (SMMT) Gets a Hold from Barclays

Kelsey Goodwin

Piper Sandler

$16

Hold

17.13%

Upside

Reiterated

07/24/26

Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT)

Yigal Nochomovitz

Citi

$40

Buy

192.83%

Upside

Reiterated

07/24/26

Buy Rating Reaffirmed on Robust HARMONi Data and BLA Progress; $40 Price Target Maintained

Mitchell Kapoor

H.C. Wainwright

―

Hold

―

Reiterated

07/24/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Molina Healthcare (NYSE: MOH) and Johnson & Johnson (NYSE: JNJ)

Bradley Canino

Guggenheim

$40→$38

Buy

178.18%

Upside

Assigned

07/23/26

Summit Therapeutics price target lowered to $38 from $40 at GuggenheimSummit Therapeutics price target lowered to $38 from $40 at Guggenheim

Jeffrey Walch

Bernstein

$7.7→$9.8

Sell

-28.26%

Downside

Reiterated

06/21/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (NASDAQ: DMRA), Summit Therapeutics (NASDAQ: SMMT) and Elicio Therapeutics (NASDAQ: ELTX)

Cory Kasimov

Evercore ISI

$34

Buy

148.90%

Upside

Reiterated

05/01/26

Evercore ISI Sticks to Their Buy Rating for Summit Therapeutics (SMMT)

Asthika Goonewardene

Truist Financial

$35

Buy

156.22%

Upside

Reiterated

02/24/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (NYSE: HUM), Summit Therapeutics (NASDAQ: SMMT) and Intuitive Surgical (NASDAQ: ISRG)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Summit Therapeutics initiated with a Peer Perform at Wolfe ResearchSummit Therapeutics initiated with a Peer Perform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Summit Therapeutics

3 Months

Asthika GoonewardeneTruist Financial

Success Rate

6/11 ratings generated profit

Average Return

+0.95%

Copying Asthika Goonewardene's trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +0.95% per trade.

1 Year

Bradley CaninoGuggenheim

Success Rate

5/11 ratings generated profit

Average Return

+135.04%

Copying Bradley Canino's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +135.04% per trade.

2 Years

Bradley CaninoGuggenheim

Success Rate

4/11 ratings generated profit

Average Return

+81.29%

Copying Bradley Canino's trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of +81.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SMMT Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SMMT has received 22 Buy Ratings, 12 Hold Ratings, and 3 Sell Ratings. SMMT average Analyst price target in the past 3 months is 27.68.

Each month's total comprises the sum of three months' worth of ratings.

SMMT Financial Forecast

SMMT Earnings Forecast

Next quarter’s earnings estimate for SMMT is -$0.28 with a range of -$0.42 to -$0.15. The previous quarter’s EPS was -$0.28. SMMT beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.74% of the time in the same period. In the last calendar year SMMT has Outperformed its overall industry.

SMMT Sales Forecast

Next quarter’s sales forecast for SMMT is $154.00K with a range of $0.00 to $1.00M. The previous quarter’s sales results were $0.00. SMMT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 39.76% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.

SMMT Stock Forecast FAQ

What is SMMT’s average 12-month price target, according to analysts?

Based on analyst ratings, Summit Therapeutics’s 12-month average price target is 27.68.

What is SMMT’s upside potential, based on the analysts’ average price target?

Summit Therapeutics has 102.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SMMT a Buy, Sell or Hold?

Summit Therapeutics has a consensus rating of Moderate Buy which is based on 7 buy ratings, 4 hold ratings and 1 sell ratings.

What is Summit Therapeutics’s price target?

The average price target for Summit Therapeutics is 27.68. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $41.00 ,the lowest forecast is $9.80. The average price target represents 102.64% Increase from the current price of $13.66.

What do analysts say about Summit Therapeutics?

Summit Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of SMMT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Summit Therapeutics (SMMT) Stock Forecast & Price Target

SMMT Analyst Ratings

SMMT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Summit Therapeutics

SMMT Analyst Recommendation Trends

SMMT Financial Forecast

SMMT Earnings Forecast

SMMT Sales Forecast

SMMT Stock Forecast FAQ

Detailed List of Analyst Forecasts